View article

Introduction

Brentuximab vedotin is an antibody-drug conjugate targeting CD30 that is a transmembrane glycoprotein of the tumor necrosis factor receptor superfamily. CD30 is involved in signal transduction via the activation of the NF-κB pathway and mitogen-activated protein kinases. CD30 is a non-lineage-specific activation marker expressed by B and T cells. Thus, a subset of T-cell lymphomas such as peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) as well as B-cell lymphomas such as EB virus positive diffuse large B-cell lymphoma (DLBCL) may also express CD30. Therefore, brentuximab vedotin may have therapeutic activities against CD30-positive non-Hodgkin lymphoma (NHL) like the previously reported promising outcome of Hodgkin and anaplastic large cell lymphoma (ALCL). In this study, we explored the efficacy of brentuximab vedotin as a salvage treatment in CD30-positive NHL …